NIH Archives - Page 3 of 3 - Medical Design Sourcing

iotaMotion lands $1.65M NIH grant to develop robotic cochlear implant tech

Robotic surgical technology developer iotaMotion announced that it received a $1.65 million grant from the National Institutes of Health (NIH).

Iowa City, Iowa-based iotaMotion said in a news release that it is using the grant funds to continue developing its real-time tissue trauma sensing technology in the iotaSoft robotic surgical system designed for assistance in cochlear implantation surgery.

The iotaSoft system is a robot-assisted insertion device designed to allow surgeons to advance cochlear implant electrodes with more control and precision, which the company believes will allow for less surgical variability.

In addition to the NIH grant, iotaMotion said it received the inaugural Iowa Biosciences Medtech Award. The $20,000 prize recognizes significant progress and investor support over the last year and has been earmarked for supporting regulatory and pre-commercialization efforts.

“These NIH funds will be used to advance technology…

NIH to boost COVID-19 testing capabilities

[Photo by Fusion Medical Animation on Unsplash]

The National Institutes of Health announced a $129.3 million plan to support scaling and manufacturing for COVID-19 tests.

As part of its Rapid Acceleration of Diagnostics (RADx) initiative, NIH is awarding contracts to nine companies for their technologies that include portable point-of-care tests for immediate results and high-throughput laboratories that can produce results in 24 hours.

Yesterday’s announcement follows a July investment in seven companies from NIH worth $248.7 million in new technologies to address challenges with COVID-19 testing.

Some of the testing technologies are also being supported by the Biomedical Advanced Research and Development Authority (BARDA) as part of the U.S. Dept. of Health and Human Services, along with Defense Advanced Research Projects Agency (DARPA), in the U.S. Defense Dept.

Here are the nine co…

Does plasma therapy work against COVID-19? NIH panel says data lacking

[Photo by Fusion Medical Animation on Unsplash]

More than a week after the FDA granted an emergency use authorization (EUA) for the use of convalescent plasma against COVID-19, an NIH advisory panel is saying that there is insufficient data to recommend either for or against the treatment.

The National Institutes of Health’s COVID-19 Treatment Guidelines Panel said in a statement released today: “There are currently no data from well-controlled, adequately powered, randomized clinical trials that demonstrate the efficacy and safety of convalescent plasma for the treatment of COVID-19.”

Get the full story on our sister site Medical Design & Outsourcing.

Does plasma therapy work against COVID-19? NIH panel says data lacking

[Photo by Fusion Medical Animation on Unsplash]

More than a week after the FDA granted an emergency use authorization (EUA) for the use of convalescent plasma against COVID-19, an NIH advisory panel is saying that there is insufficient data to recommend either for or against the treatment.

The National Institutes of Health’s COVID-19 Treatment Guidelines Panel said in a statement released today: “There are currently no data from well-controlled, adequately powered, randomized clinical trials that demonstrate the efficacy and safety of convalescent plasma for the treatment of COVID-19.”

FDA commissioner Stephen Hahn already apologized on Twitter last week after heavy criticism for his statement that convalescent plasma donated by former coronavirus patients could reduce COVID-19 deaths by 35% — criticism that he acknowledged was justified. The FDA has taken heat over its decisionmaking a…